Refine
Year of publication
Document Type
- Article (114)
- Preprint (35)
- Conference Proceeding (3)
- Working Paper (2)
- Book (1)
- Report (1)
Has Fulltext
- yes (156)
Is part of the Bibliography
- no (156)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- LHC (7)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- ALICE (3)
- ALICE experiment (3)
- Hadron-Hadron Scattering (3)
- metastatic (3)
- pp collisions (3)
- Alpelisib (2)
- Atezolizumab (2)
- Beauty production (2)
- Diagnostik (2)
- Früherkennung (2)
- Katherine (2)
- Lokalrezidiv (2)
- Nachsorge (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Single electrons (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- treatment/therapy (2)
- 900 GeV (1)
- Advanced breast cancer (1)
- Aeroplysinin-1 (1)
- Anti-seizure medication (1)
- Antihormone therapy (1)
- Artificial Intelligence (1)
- B cell malignancies (1)
- Bezeichnungen (1)
- Bibliometrics (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Bone cancer (1)
- Botanical Collections (1)
- Brain metastasis (1)
- Breast cancer (1)
- CD74 (1)
- COVID (1)
- COVID-19 (1)
- CVID (1)
- Cancer genetics (1)
- Capecitabine (1)
- Central nervous system metastases (1)
- Charm physics (1)
- Chemical biology (1)
- Chemical ecology (1)
- Circulating MiRNA (1)
- Citation analysis (1)
- Clinical Trials and Observations (1)
- Clinical variation (1)
- Cognitive impairment (1)
- Comparison with QCD (1)
- Computerlinguistik (1)
- Computerspielstörung (1)
- Conservation (1)
- DNA sequencing (1)
- Digitization (1)
- Elderly (1)
- Environmental chemistry (1)
- Epilepsy (1)
- Epithelioma Cells (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Extended donor criteria (1)
- Femtoscopy (1)
- First site of metastatic disease (1)
- Frailty (1)
- Gene regulation (1)
- General practitioners (1)
- Generic NLP Architecture (1)
- German PID-NET registry (1)
- Glücksspielstörung (1)
- HBT (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- HLA class II (1)
- HLA peptidome (1)
- HPSG Parsing (1)
- Hadron production (1)
- Heavy Ions (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Herbaria (1)
- Heregulin (1)
- Hypertension (1)
- ICD-11 (1)
- IE (1)
- Iceland (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Jets (1)
- Konsumgenossenschaft (1)
- Liver Fibrosis (1)
- Lymphoma Cells (1)
- MM-121 (1)
- Machine learning (1)
- Metastatic (1)
- Metastatic breast cancer (1)
- MiR-29 (1)
- Mid-rapidity (1)
- Molecular subtypes (1)
- Multi-strange baryons (1)
- Myeloid Neoplasia (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- Nuclear modification factor (1)
- Oldest-old (1)
- Organ allocation (1)
- PELICAN (1)
- PID prevalence (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parkinson disease (1)
- Pb–Pb (1)
- Pegylated liposomal doxorubicin (1)
- Proton–proton (1)
- Rejection (1)
- Relativistic heavy ion physics (1)
- Research Infrastructure (1)
- Rhabdomyoma (1)
- SARS-CoV-2 (1)
- Scientific publishing (1)
- Scientists (1)
- Seizure (1)
- Semantics (1)
- Seribantumab (1)
- Shallow NLP (1)
- Single muons (1)
- T-DM1 (1)
- Taxonomy (1)
- Transverse momentum (1)
- Tumor heterogeneity (1)
- Tumor infiltrating lymphocytes (1)
- Verhaltenssucht (1)
- XML (1)
- accident (1)
- advanced breast cancer (1)
- antihormone therapy (1)
- behavioral addiction (1)
- cancer (1)
- chemotherapy (1)
- chronic kidney disease (CKD) (1)
- dementia (1)
- dialysis (1)
- diffusion tensor imaging (1)
- full-contour zirconia (1)
- fungal traits (1)
- gambling disorder (1)
- gaming disorder (1)
- global biomes (1)
- grinding (1)
- injury (1)
- lapatinib (1)
- latitudinal gradient (1)
- lockdown (1)
- mTOR inhibitor (1)
- magnetic resonance imaging (1)
- mean fruit body size (1)
- metastasis (1)
- mild cognitive impairment (1)
- neutralizing antibodies (1)
- pancreatic cancer (1)
- parathormone (PTH) (1)
- paricalcitol (1)
- pediatric intensive care (1)
- pertuzumab (1)
- polishing (1)
- predialysis (1)
- primary immunodeficiency (PID) (1)
- registry for primary immunodeficiency (1)
- roughness (1)
- saprobic and ectomycorrhizal basidiomycetes (1)
- secondary hyperparathyroidism (sHPT) (1)
- spectra (1)
- spike protein (1)
- terminology (1)
- trastuzumab (1)
- trauma (1)
- variants of concern (1)
- veneering porcelain (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (89)
- Frankfurt Institute for Advanced Studies (FIAS) (68)
- Informatik (68)
- Medizin (46)
- Geowissenschaften (8)
- Biochemie und Chemie (4)
- Biowissenschaften (3)
- ELEMENTS (1)
- Extern (1)
- Georg-Speyer-Haus (1)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren.
Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden.
Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.
Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer.
Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure.
Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.
Long-range angular correlations on the near and away side in p–Pb collisions at √sNN=5.02 TeV
(2013)
Angular correlations between charged trigger and associated particles are measured by the ALICE detector in p–Pb collisions at a nucleon–nucleon centre-of-mass energy of 5.02 TeV for transverse momentum ranges within 0.5<pT,assoc<pT,trig<4 GeV/c. The correlations are measured over two units of pseudorapidity and full azimuthal angle in different intervals of event multiplicity, and expressed as associated yield per trigger particle. Two long-range ridge-like structures, one on the near side and one on the away side, are observed when the per-trigger yield obtained in low-multiplicity events is subtracted from the one in high-multiplicity events. The excess on the near-side is qualitatively similar to that recently reported by the CMS Collaboration, while the excess on the away-side is reported for the first time. The two-ridge structure projected onto azimuthal angle is quantified with the second and third Fourier coefficients as well as by near-side and away-side yields and widths. The yields on the near side and on the away side are equal within the uncertainties for all studied event multiplicity and pT bins, and the widths show no significant evolution with event multiplicity or pT. These findings suggest that the near-side ridge is accompanied by an essentially identical away-side ridge.
The differential charged jet cross sections, jet fragmentation distributions, and jet shapes are measured in minimum bias proton-proton collisions at centre-of-mass energy s√=7 TeV using the ALICE detector at the LHC. Jets are reconstructed from charged particle momenta in the mid-rapidity region using the sequential recombination kT and anti-kT as well as the SISCone jet finding algorithms with several resolution parameters in the range R=0.2 to 0.6. Differential jet production cross sections measured with the three jet finders are in agreement in the transverse momentum (pT) interval 20<pjet,chT<100 GeV/c. They are also consistent with prior measurements carried out at the LHC by the ATLAS collaboration. The jet charged particle multiplicity rises monotonically with increasing jet pT, in qualitative agreement with prior observations at lower energies. The transverse profiles of leading jets are investigated using radial momentum density distributions as well as distributions of the average radius containing 80% (⟨R80⟩) of the reconstructed jet pT. The fragmentation of leading jets with R=0.4 using scaled pT spectra of the jet constituents is studied. The measurements are compared to model calculations from event generators (PYTHIA, PHOJET, HERWIG). The measured radial density distributions and ⟨R80⟩ distributions are well described by the PYTHIA model (tune Perugia-2011). The fragmentation distributions are better described by HERWIG.
The ALICE collaboration at the LHC reports measurement of the inclusive production cross section of electrons from semi-leptonic decays of beauty hadrons with rapidity |y|<0.8 and transverse momentum 1<pT<10 GeV/c, in pp collisions at s√= 2.76 TeV. Electrons not originating from semi-electronic decay of beauty hadrons are suppressed using the impact parameter of the corresponding tracks. The production cross section of beauty decay electrons is compared to the result obtained with an alternative method which uses the distribution of the azimuthal angle between heavy-flavour decay electrons and charged hadrons. Perturbative QCD calculations agree with the measured cross section within the experimental and theoretical uncertainties. The integrated visible cross section, σb→e=3.47±0.40(stat)+1.12−1.33(sys)±0.07(norm)μb, was extrapolated to full phase space using Fixed Order plus Next-to-Leading Log (FONLL) predictions to obtain the total bb¯ production cross section, σbb¯=130±15.1(stat)+42.1−49.8(sys)+3.4−3.1(extr)±2.5(norm)±4.4(BR)μb.
The ALICE collaboration at the LHC reports measurement of the inclusive production cross section of electrons from semi-leptonic decays of beauty hadrons with rapidity |y|<0.8 and transverse momentum 1<pT<10 GeV/c, in pp collisions at s√= 2.76 TeV. Electrons not originating from semi-electronic decay of beauty hadrons are suppressed using the impact parameter of the corresponding tracks. The production cross section of beauty decay electrons is compared to the result obtained with an alternative method which uses the distribution of the azimuthal angle between heavy-flavour decay electrons and charged hadrons. Perturbative QCD calculations agree with the measured cross section within the experimental and theoretical uncertainties. The integrated visible cross section, σb→e=3.47±0.40(stat)+1.12−1.33(sys)±0.07(norm)μb, was extrapolated to full phase space using Fixed Order plus Next-to-Leading Log (FONLL) predictions to obtain the total bb¯ production cross section, σbb¯=130±15.1(stat)+42.1−49.8(sys)+3.4−3.1(extr)±2.5(norm)±4.4(BR)μb.
We report the first measurement at the LHC of coherent photoproduction of ρ0 mesons in ultra-peripheral Pb-Pb collisions. The invariant mass and transverse momentum distributions for ρ0 production are studied in the π+π− decay channel at mid-rapidity. The production cross section in the rapidity range |y|<0.5 is found to be dσ/dy=425±10(stat.) +42−50(sys.) mb. Coherent ρ0 production is studied with and without requirement of nuclear breakup, and the fractional yields for various breakup scenarios are presented. The results are compared with those from lower energies and with model predictions.
We report the first measurement at the LHC of coherent photoproduction of ρ0 mesons in ultra-peripheral Pb-Pb collisions. The invariant mass and transverse momentum distributions for ρ0 production are studied in the π+π− decay channel at mid-rapidity. The production cross section in the rapidity range |y|<0.5 is found to be dσ/dy=425±10(stat.) +42−50(sys.) mb. Coherent ρ0 production is studied with and without requirement of nuclear breakup, and the fractional yields for various breakup scenarios are presented. The results are compared with those from lower energies and with model predictions based on the Glauber model and the color dipole model. The measured cross section is found to be inconsistent with a scaling of the γ-nucleon cross section using the Glauber model.
Prompt D meson and non-prompt J/ψ yields are studied as a function of the multiplicity of charged particles produced in inelastic proton-proton collisions at a centre-of-mass energy of s√=7 TeV. The results are reported as a ratio between yields in a given multiplicity interval normalised to the multiplicity-integrated ones (relative yields). They are shown as a function of the multiplicity of charged particles normalised to the average value for inelastic collisions (relative charged-particle multiplicity). D0, D+ and D∗+ mesons are measured in five pT intervals from 1 to 20 GeV/c and for |y|<0.5 via their hadronic decays. The D-meson relative yield is found to increase with increasing charged-particle multiplicity. For events with multiplicity six times higher than the average multiplicity of inelastic collisions, a yield enhancement of a factor about 15 relative to the multiplicity-integrated yield in inelastic collisions is observed. The yield enhancement is independent of transverse momentum within the uncertainties of the measurement. The D0-meson relative yield is also measured as a function of the relative multiplicity at forward pseudorapidity. The non-prompt J/ψ, i.e. the B hadron, contribution to the inclusive J/ψ production is measured in the di-electron decay channel at central rapidity. It is evaluated for pT>1.3 GeV/c and |y|<0.9, and extrapolated to pT>0. The fraction of non-prompt J/ψ in the inclusive J/ψ yields shows no dependence on the charged-particle multiplicity at central rapidity. Charm and beauty hadron relative yields exhibit a similar increase with increasing charged-particle multiplicity. The measurements are compared to PYTHIA 8, EPOS 3 and percolation calculations.